BMJ Examines Risks of Incretin Therapy
(MedPage Today) -- Incretin mimetics may be more risky than previously thought, given that drug companies have held back data on their potentially harmful effects, says the BMJ. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - June 12, 2013 Category: Cardiology Source Type: news
Merck Welcomes Independent Review of the Safety Profile of JANUVIA® (sitagliptin) and Other Diabetes Medicines
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck, known as MSD outside the United States and Canada, today issued
the following statement regarding this week's NIDDK-NCI Workshop and the
American Diabetes Association’s (ADA) call for an independent review of
data about the safety of incretin-based diabetes medicines, including
GLP-1 analogs and DPP-4 inhibitors such as JANUVIA®
(sitagliptin).
Language:
English
...
Source: Merck.com - Product News - June 12, 2013 Category: Drugs & Pharmacology Authors: hq_site_admin Tags: Prescription Medicine News Corporate News Latest News Source Type: news
Effects of GLP1R agonists on primary thyroid C-cells
Glucagon-like peptide 1 (GLP1) is an incretin hormone that promotes glucose-dependent stimulation of insulin and suppression of glucagon secretion, delays gastric emptying, and reduces energy intake. GLP1 also increases β-cell mass via stimulation of β-cell proliferation. The actions of GLP1 are mediated by a GLP1 receptor (GLP1R).
Boess et al. aimed to establish primary thyroid cell cultures of rat and human to evaluate the expression and function of GLP1R in C-cells as functional C-cell response has rarely been demonstrated.
They succeeded in establishing primary thyroid cell culture systems...
Source: Society for Endocrinology - June 12, 2013 Category: Endocrinology Source Type: news
Diabetes drugs may be linked to pancreatic cancer
Conclusion
This article presents important concerns that glucagon-like peptide-1 (GLP-1) agonists and dipeptidylpeptidase-4 (DPP-4) inhibitors could potentially increase the risk of inflammation and cancerous changes in the pancreas.
The agencies that regulate medicines in Europe and the USA are aware of these issues, and told the BMJ that their analyses show increased reporting of pancreatic cancer among people taking these types of drugs.
However, the agencies note that it has not been established whether these drugs directly cause the adverse effects seen in the pancreas. Both agencies are reviewing emerging eviden...
Source: NHS News Feed - June 10, 2013 Category: Consumer Health News Tags: Medication Diabetes QA articles Source Type: news
Researchers Face Off Over Incretin Risk
(MedPage Today) -- As concerns escalate over the potential risks of glucagon-like peptide-1 (GLP-1)-based therapies, a diabetes journal hosted a point-counterpoint debate between the researchers who have been the leading voices on each side of the issue. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - May 17, 2013 Category: Cardiology Source Type: news
Safety of Incretin-Based Therapies Hotly Debated Safety of Incretin-Based Therapies Hotly Debated
Should clinicians worry about possible cancer risks with incretin mimetic drugs for type 2 diabetes? Yes, say some experts. No, says another, arguing that substantial evidence is lacking. Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - May 8, 2013 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news
Report Shows Byetta, Januvia and Other Incretin Mimetic Drugs for Type...
According to the Institute for Safe Medication Practices’ most recent QuarterWatch report, incretin mimetic drugs such as Byetta, Januvia and Victoza may be 25 times more likely to be linked to...(PRWeb April 19, 2013)Read the full story at http://www.prweb.com/releases/Byetta-Januvia-cancer/04/prweb10653663.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - April 23, 2013 Category: Pharmaceuticals Source Type: news
Exendin-4 prevents lipoapoptosis
Type 2 diabetes and insulin resistance are associated with atherosclerosis, which is the major cause of morbidity and mortality in these patients. Experimental studies have indicated that endothelial cells play an important role in maintaining vascular homeostasis.
Erdogdu et al. conducted a study to investigate the putative protective effect of exendin-4 (a stable incretin mimetic and GLP1 receptor agonist) and GLP1 against lipoapoptosis of HCAECs and attempt to address the pathways involved in imparting such an effect.
They found that long-term exposure of HCAECs to palmitate induces apoptosis, eNOS activity, ROS release...
Source: Society for Endocrinology - April 11, 2013 Category: Endocrinology Source Type: news
Popular Diabetes Drugs May Harm The Pancreas
Type 2 diabetes patients who are on incretin therapy have a higher risk of developing abnormalities in their pancreas compared to their counterparts on other types of diabetes therapies, researchers from the Larry L. Hillblom Islet Research Center at UCLA and the Diabetes Center at the University of Florida reported in the journal Diabetes. The scientists explained that patients on incretin therapy were more likely to have rapid multiplication of pancreatic cells that may be associated with a higher risk of neuroendocrine tumors... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 1, 2013 Category: Consumer Health News Tags: Diabetes Source Type: news
EU Will Study Risks of Incretin Mimetics for DiabetesEU Will Study Risks of Incretin Mimetics for Diabetes
Like their US counterparts, European regulators will investigate the findings of a recent study suggesting an increased risk for precancerous cellular changes in the pancreas as well as pancreatitis. News Alerts (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 27, 2013 Category: Consumer Health News Tags: Diabetes & Endocrinology News Alert Source Type: news
Incretins Beef Up Pancreas (CME/CE)
(MedPage Today) -- Incretin therapy increased pancreatic mass and beta cell mass in patients with type 2 diabetes, potentially putting patients at risk for malignancies, researchers found. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 27, 2013 Category: Cardiology Source Type: news
Research suggests popular diabetes drugs can cause abnormal pancreatic growth in humans
Individuals who had taken a type of drug commonly used to treat Type 2 diabetes showed abnormalities in the pancreas, including cell proliferation, that may be associated with an increased risk of neuroendocrine tumors, according to a new study by researchers from UCLA and the University of Florida. Their findings were published online March 22 in the journal Diabetes.
The researchers, from the Larry L. Hillblom Islet Research Center at UCLA and the Diabetes Center at the University of Florida, found that cell mass was increased approximately 40 percent in the pancreases of deceased organ donors who had Type 2 ...
Source: UCLA Newsroom: Health Sciences - March 26, 2013 Category: Universities & Medical Training Source Type: news
FDA Probing Risk of Pancreatitis with Incretins
(MedPage Today) -- The FDA said Thursday it is reviewing unpublished data that point toward an increased risk of pancreatitis and precancerous changes in type 2 diabetes patients who are treated with drugs in the incretin class. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 14, 2013 Category: Cardiology Source Type: news
FDA to Examine Pancreatic-Duct Metaplasia With IncretinsFDA to Examine Pancreatic-Duct Metaplasia With Incretins
The FDA has issued a drug safety communication alerting patients and doctors to a possible association between incretin mimetic diabetes drugs and precancerous changes in the pancreas. News Alerts (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 14, 2013 Category: Consumer Health News Tags: Diabetes & Endocrinology News Alert Source Type: news
Incretin Mimetic Drugs for Type 2 Diabetes: Early Communication - Reports of Possible Increased Risk of Pancreatitis and Pre-cancerous Findings of the Pancreas
Unpublished new findings by a group of academic researchers suggest an increased risk of pancreatitis and pre-cancerous cellular changes called pancreatic duct metaplasia. (Source: FDA MedWatch)
Source: FDA MedWatch - March 14, 2013 Category: American Health Source Type: news
